Evaluation of omega-3 in reduction of myocardal damage in patients with myocardial infarctions who undergoing streptokinase therapy

A Randomized placebo controlled trial of Omega-3 on Plasma Level of Cardiac Troponin-I and Creatinine Kinase- MB in patients with myocardial infarctions who undergoing streptokinase therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402078307N5

Enrollment

100

Registered

2014-10-10

Start date

2013-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction. Myocardial Infarction

Interventions

Intervention 1: Intervention: in omega-3 group All patients will be received 3 grams of omega-3 before streptokinase injection. Intervention 2: Control: In the control group, patients only will be gi

Treatment - Drugs

Intervention: in omega-3 group All patients will be received 3 grams of omega-3 before streptokinase injection.

Control: In the control group, patients only will be given the standard treatment.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: myocardial infarction patients; age 18-80; undergoing of thrombolytic therapy with streptokinase; filling of consent form. Exclusion Criteria: Elevation of CK-MB and cTnI before injection of streptokinase; history of CABG during last three months; history of previous MI; renal dysfunction (creatinine above 2.5 mg/dl); contraindication of streptokinase therapy; acute MI; cardiogenic shock; Hypersensitivity to aspirin or clopidogrel or omega-3 and streptokinase injection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CK-MB level. Timepoint: Before, 8 and 24 hours after streptokinase injection. Method of measurement: ELISA kits.	—

Secondary

Measure	Time frame
CTnI level. Timepoint: Before, 8 and 24 hours after streptokinase injection. Method of measurement: ELISA kits.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026